BxRx is a computational cancer drug combination prediction and validation solution in 3D cell models of patient tumors.
BxRX works as a platform-as-a-service that will support the work of clinical development in Pharma & Biotech companies.
The solution is based on a computational evidence-based network medicine platform for improving success in drug development by providing deeper insights and accelerating the process of finding the right indication & patient for the right drugs through big data analytics and AI, by using Natural Language Processing, Machine Learning, and Graph Analytics algorithms together with public/private medical records, clinical trials, (bio)medical literature, and genomics data.
This data will then be validated in cancer patient-derived tumor biopsy models that can be cultured in 3D, mimicking the actual tumor micro-environment, to test if the treatment works, before it’s given to the patient.

BXRX’s expectations from the acceleration programme:

DigiCirc financial support: €117,500

The financial support was used for advancements in the prototype, perform tests and prepare marketing materials.